The clinical trials preliminarily demonstrated that these three bsAb drugs were well tolerated and achieved comparable efficacy as trastuzumab and pertuzumab in pretreated patients with HER2-positive breast cancer [90,91]. Here, ERBB2 is linked to breast cancer.